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Long-standing psychiatric practice confirms the pervasive use of 
pharmacological therapies for treating severe mental disorders. In many 
circumstances, drugs constitute the best allies of psychotherapeutic 
interventions. A robust scientific literature is oriented on finding the best 
strategies to improve therapeutic efficacy through different modes and 
timing of combined interventions. Nevertheless, we are far from triumphal 
therapeutic success. Despite the advances made by neuropsychiatry, this 
medical discipline remains lacking in terms of diagnostic and prognostic 
capabilities when compared to other branches of medicine. An ethical 
principle remains as the guidance of therapeutic interventions: improving 
the quality of life for patients. Unfortunately, psychotropic drugs and 
psychotherapies do not always result in an efficient remission of symptoms. 
In this paper I corroborate the idea that therapists should provide drug-
resistant patients with every effective and available treatment, even if some 
of such interventions could be invasive, like Electroconvulsive Therapy 
(ECT). ECT carries upon its shoulders a long and dramatic history that 
should be better investigated to provide new insights. In fact, ECT has 
attracted renewed interest in recent years. This is due to the fact that 
antidepressant drugs in younger patients show often scarce effectiveness 
and unpleasant side-effects. Moreover, I show that, thanks to modern 
advances, ECT may work as a successful form of treatment for specific and 
rare cases, such as severe depression (with suicide attempts) and catatonia. 
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“The story of psychiatry is a story of tensions that have not yet played out. It is a 
history where what we decide is the truth regarding our past has immediate and 
profound implications for how we view ourselves and our futures and how we treat 
others when they are at their most vulnerable. It is a history that affects all of us.” 
(Healy 2002, 8) 
 
1. The History of a Euphoria 
 
Electroconvulsive therapy has an almost centennial history that began in 
Rome (Italy) in 1938, at the Clinic of Nervous and Mental Diseases, run at 
the time by (psychiatrist) Ugo Cerletti. ECT still represents one of the most 
important and controversial therapeutic discoveries in the field of 
psychiatry. It is based on the passage of short electrical impulses that cause 
convulsions. Unlike insulin, and still more than the drug Metrazol used by 
von Meduna to provoke convulsions but with severe side effects (Shorter 
and Healy 2007), electricity could be administered to patients in subtly 
graded doses. This way, the convulsions, which were considered by 
psychiatrists to be the essential therapeutic ingredient, would be less 
dangerous and easier to manage (Passione 2004, 89).  
 
After the first official presentation of electroshock (E.S., as ECT was called 
at that time) to a restricted audience, Cerletti waited two years before the 
publication of a detailed account of his research in the Rivista sperimentale 
di freniatria (Cerletti 1940). Cerletti was probably aware of the potential 
risks involved in the dissemination of ECT, and he wanted to avoid hasty 
imitators applying E.S. with too little experience. He also believed that 
publicity about his discovery would have sounded inappropriate before a 
thorough analysis of “the best modes of application of E.S.” was completed 
(Cerletti 1940). The long and detailed essays by Bini (1940) “La Tecnica 
e le manifestazioni dell’Elettroshock”, testify that the inventors of this 
technique, namely Cerletti and Bini himself, were extremely careful and 
cautious to carry out electroconvulsive treatment (Passione 2004, 90-91).  
 
However, their advice was not followed. The rapid dissemination of ECT 
in Western countries was due to Lothar Kalinowsky, a Jewish student of 
Cerletti emigrated from Italy to England because of the racial laws 
promulgated in 1938 during the Fascist regime. The application of the 
therapy occurred in every conceivable way (Berrios 1997; Shorter 1997). 
From England to France, to Germany and to the United States, where 
another collaborator of Cerletti, Renato Almansi, taught the E.S. technique 
to David Impastato, who treated the first American patient, a 29-year-old 
schizophrenic woman in 1940 (Passione 2004, 93). 
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At the XXIII Congress of the Italian Society of Psychiatry held in 1946, 
Cerletti denounced the non-scientific use of the recent shock therapeutic 
discoveries. In the same congress, psychiatrists Baldi and Reale raised the 
same question about the indiscriminate abuse of shock therapies, in 
particular ECT, for all types of mental illness. They posited the need to 
“arrive at a clearer definition of its field of application and restrict its use 
accordingly” (Baldi and Reale 1947; Passione 2004, 96). Max Fink, one of 
the most famous American psychiatrists who practiced and taught ECT 
throughout his long career, has well described these initial phases in an 
interview with Shorter and Healy in 2002. He claimed: “The problem at 
the beginning was what is necessary for an effect. It was [easier] to get 
seizures. But they didn’t know what was important, so they tried sub 
convulsive, they tried convulsive, they tried multiple seizures, they tried 
different electrode pairs, with drugs, without drugs, daily treatments, twice 
daily” (Shorter and Healy 2007, 140). 
 
As patient and clinical reports attest, it was not uncommon for E.S. to be 
administered without a real therapeutic need and in combination with 
insulin therapy and psychotropic drugs.1 In some cases, E.S. was 
unfortunately used as a deterrent or even as a threat. These repeated 
occurrences contributed to the creation of stigma surrounding ECT and to 
its wrongful assimilation to a barbaric practice.  
 
Every catatonic or schizophrenic patient was the ideal candidate, together 
with adolescents and children. The first minor patients treated with ECT 
were believed to have been in France starting in 1941 by George Heuyer 
and colleagues, and in the United States starting in 1942 by Lauretta 
Bender (see Shorter 2013).2 However, from the examination of the 
Archives of Pediatric Neuropsychiatry in Rome—a section of the Roman 
Clinic specifically dedicated to minors3—it emerges that the first child ever 
administered with ECT (September 18, 1940) was a 7-year-old boy 
diagnosed with “dementia praecocissima”.4 After 23 applications of the 
technique, the child was discharged and returned to the father, who had 
assisted him during the preparation of the first session. Another child (a 
 
1 For the Italian case, see Nemec (2015) who discusses several clinical reports and 
treatments relative to the post-WWII era in Trieste and Gorizia.  
2 See also Walter et al. (2010). 
3 The hospital section devoted to minors was established by the Director Sante de Sanctis 
in 1930 (Coccanari de’ Fornari et al. 2017). 
4 Historical Archives of Child Neuropsychiatry – Department of Human Neuroscience 
(Sapienza University of Rome), volume n. 18, record 1682. The ordering of the medical 
records which are in the Historical Archives follows an arrangement by years. For a review 




six-year-old boy) with the same diagnosis was treated with E.S. in 1943. 
Before and after them, a few other children and adolescents were treated 
with insulin shock therapies. The first catatonic young patient treated with 
E.S. was a 14-year-old girl in 1944. After 11 applications, the girl had a 
remission of symptoms and was discharged from the clinic and returned to 
her family. She relapsed years later and was readmitted to the clinic in 
December 1950.  Accornero and Anderson (1948) reported a sample of 
E.S. treatments which regarded infant and young adolescent patients of the 
Roman clinic. Among these cases is also the first one I mentioned.5 
Compared to the original medical record, the article by Accornero and 
Anderson does not provide many other data. In general, the medical 
records of those years often report a detailed anamnesis. However, the 
outcome of the treatments is hard to obtain. Accornero and Anderson's 
essay has the merit of deepening this aspect for some of the 15 cases of 
prepubertal schizophrenia they examined. This way, we come to discover 
that Gianluigi, this is the name of the first child, is discharged from the 
Clinic in the same conditions in which he entered. Furthermore, the 
frequency of treatments is well specified in the paper (the first 12 
applications twice a week and the other ones three times a week). The 
authors also specify the standard voltage: 110 or 120 Volt in 1/10 per 
second (Accornero and Anderson 1948, 233-234). Accornero and 
Anderson's conclusive analysis is pessimistic about the efficacy of ECT in 
childhood psychosis. The authors were aware of the small sample of 
patients, and mightily complained of the difficulty in providing a more 
detailed diagnosis. The vagueness of the diagnosis increased the empiricity 
of the therapeutic method which was already empirical. 
 
The archives of the Roman Clinic of Nervous and Mental Diseases also 
bring to light the existence of an informed consent form that families (or 
caretakers) were asked to sign, albeit in a primitive form. In the E.S. 
Collection, established by the Director Cerletti, there are the primitive 
informed consent forms that the parents, relatives or tutors had to fill in. 
Initially, in 1937, the informed consent only concerned insulin therapy and 
it had later been extended to ECT. It recited as follows: 
 
[On letterhead R.[oyal] University of Rome. Clinic of Nervous 
and Mental Diseases] I have been made aware of the dangers 
that shock therapies pose in some cases. Given that these 
treatments are today those that give some hope for 
improvement, I adhere to the proposal to practice it in my son 
 
5 It is worth noting that Felice Accornero helped Cerletti and Bini in making the ECT device 
(Sirgiovanni and Aruta 2020, 321). Thus, two remarkable researchers had already reported 
the very first case of E.S. in children, although they did not underline this peculiarity. 
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[or other family member] [name and surname of the patient], 
releasing the R[oyal] Clinic from any responsibility. [Original 
signature].6 
 
Nowadays, patients are routinely told why a certain treatment is prescribed, 
and the administration procedures are explained in detail. At the time, of 
course, each patient had to sign informed consent forms where all this 




2. From Euphoria to Barbarities 
 
From its beginning in 1938 throughout the 1950s, ECT gained wide fame 
for the treatment of schizophrenia. Those who have the opportunity to 
consult old medical records dating back to those years may realize the 
series of therapeutic success, partial symptomatic remissions, cyclic 
relapses, and consequent readmissions, as well as complete failures of 
ECT. Although this scenario cannot be considered a full-fledged victory, 
the therapeutic success attained was already an exceptional improvement, 
which could illuminate the darkness of therapeutic nihilism in which 
psychiatry as a science had been struggling for centuries. 
 
The ECT practice also revealed its efficacy for catatonia and affective 
disorders like severe depression. In a very few years, from the era of 
medical frustration where there was no other remedy than to sedate, purge 
and contain patients, and “the treatment of mental illness represented a vast 
wasteland of hopelessness” (Shorter and Healy 2007, 4), ECT appeared to 
provide fast alleviation of psychotic symptoms, above all in the acutely ill, 
without too many significant risks (see below for a discussion on ECT’s 
side effects). 
 
Throughout the 1960s and 1970s, the wide availability and dissemination 
of antipsychotic drugs, together with increasing opposition to the use of 
ECT, that went into a gradual decline (Fink 2001). During the years of 
contestations, i.e. from 1968 onward, a destructive as well as misleading 
connection was generated between the movements of psychiatry 
renovation and antipsychiatry. The former worked on changing the 
methods of interventions and limiting the restrictive measures adopted in 
asylums. The latter was against both the asylums and psychiatric 
interventions as a whole, including shock therapies and drugs. Drugs, 
which had not much earlier been acclaimed “as awakening the chronically 
 
6 My translation is from original documents, which are kept in the E.S. Collection.  
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psychotic from irretrievable madness, were now castigated as chemical 
straitjackets” (Healy 2002, 5). All of psychiatry’s past was interpreted as a 
series of barbarities culminated in E.S. and psychosurgery. Similarly, for 
many philosophers at that time, the methods of psychiatric discipline 
represented a clear and potent symbol of the irrationality of modern 
society, generated by the union between science and capitalism.7  
 
This political and cultural short circuit led to two dramatic changes, first 
of all in Italy, which acted as a pioneering country in this field. The first 
was the closure of psychiatric asylums, which in many cases had become 
institutions of arbitrary and unmotivated restraints (see Babini 2009 on the 
Italian case). The second was the abandonment of those therapeutic 
practices that were considered too invasive. This way, psychiatric 
treatments of proven effectiveness such as E.S. were banned, little by little, 
in many (Western) countries (Healy 2002, 5). A resurgence of interest in 
ECT occurred in the 1980s, following the finding that a large portion of 
patients do not tolerate or respond to drugs, or appear to be drug resistant. 
This has prompted the investigation of combining drugs with ECT. 
Furthermore, many psychiatrists suggest ECT as the treatment of choice 
for catatonic schizophrenia (Fear 2005, 30). 
 
 
3. Barefaced and Raw ECT 
 
Given these historical premises, we cannot disagree with Edward Shorter 
when he claims that ECT provides an exciting insight into the role of 
culture against science in clinical decision-making (Shorter 2013). Why 
should we reconsider ECT after a massive and historically-laden 
disengagement from this therapy? The answer is simple: ECT is an 
effective and safe treatment, with potentially low side-effects risks for 
some kinds of severe disorders. Quoting the UK National Institute for 
Clinical Excellence (NICE): “Electroconvulsive therapy is a proven 
effective treatment for depression. It is a safe form of treatment even in the 
medically ill, the elderly and in pregnancy. There are benefits in using it in 
emergencies. It should not be relegated to a treatment of last resort” 
(Lamprecht et al. 2005, 19). In fact, ECT could be  the treatment of choice 
when severe forms of depression are associated with attempts of suicide 
(or with strong suicidal plans) and urgent intervention is needed, or when 
patients present significant psychomotor retardation, stupor, depressive 
 
7 I suggest reading Giovanni Jervis on this point (2014). He was a lucid witness of the 
cultural climate in Europe and also contributed to a profound renewal of psychiatric 
interventions in Italy. For more details see also Fiorani’s article (this issue).  
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delusions or hallucinations (Lamprecht et al. 2005, 13; see also UK ECT 
Review Group 2003).  
 
Contrary to their original hopes (and promises), some kinds of 
psychotropic drugs like selective serotonin reuptake inhibitors (SSRIs) 
have been accompanied by several distressing side effects. Among them, 
decreased libido and even impotence, delayed orgasm, anorgasmia, 
anhedonia. Impotence has proven particularly troublesome, as Clayton and 
colleagues showed (2002; but see also Jacobsen et al. 2020). Furthermore, 
twenty years ago in the UK, two-thirds of SSRI patients had discontinued 
treatment by the end of the third month (Shorter 2009, 201).8  
 
When pharmacotherapy fails to improve depressive symptoms, then, 
“response rates of about 50–60% can be achieved by ECT” (Eser et al. 
2007, 2). For this reason, particularly in depressed patients at high risk of 
suicide, ECT should be recommended earlier than its conventional “last 
resort” position. In fact, the risks of suicide have been shown to relieve 
quickly through ECT, when administered in continuity with previous 
treatments, that are essential to sustain its benefits. Look, for example, at 
Kellner et al.’s (2005, 977) study, in which expressed suicidal intent in 131 
depressed patients was rapidly relieved by ECT, already after one week 
(i.e., three ECT sessions) in 38.2% of the patients, and, at the end of the 
course of treatment, in 80.9% of the patients. 
 
Furthermore, in all stages of pregnancy, ECT may represent the best 
solution in case of severe mood or thought disorders, when antidepressants 
and antipsychotics cannot be administered (Abrams 2002; Fink 2009). In 
this sense, ECT may represent a safer treatment for these more difficult 
cases.  
 
In addition to drug-resistant major depression, which remains the most 
frequent indication for ECT, other psychiatric illnesses like delusional 
mania, catatonia, malignant neuroleptic syndrome and delusional mania 
should be considered “urgent first-line indications for ECT treatment” 
(Eser et al. 2007, 2). Patient choice is obviously crucial in most cases. In 
fact, if some sufferers have already experienced ineffective or intolerable 
medical treatment, they may choose ECT; alternatively, if they had 
previous successful experiences of recovery with ECT, they can express 
the will to be administered a further cycle of treatment.9 Although ECT has 
 
8 For a review of these issues, see Holtzheimer and Mayberg (2011).  
9 Several handbooks and essays about psychiatry insert positive biographical reports about 




been recognized as “an effective treatment for mood and psychotic 
disorders, it is among patients with catatonia that the most remarkable 
efficacy is observed” (Petrides et al. 2004, 151). Although for 
uncomplicated cases of catatonia the first-line treatment should be 
benzodiazepines (Rosebush and Mazurek 2004), “for malignant catatonia, 
or in circumstances where use of benzodiazepines is contraindicated, ECT 
should be the first-line treatment” (Fear 2005, 40).  On the contrary, ECT 
is not helpful for those people affected by a lifelong history of emotional 




4. The Procedure 
 
The image of a fast, shift-like psychiatry is far from the truth: “ECT is not 
a surgical excision that removes the defect”, claims Fink. “It is more like 
the treatment of diabetes in which repeated administration of insulin and 
dietary control are needed to maintain healthy serum glucose levels” (Fink 
2013, 21). 
 
Thanks to the evolution of ECT instrumentation, which often includes 
EEG10 and EKG (for a review see Weiss 2018, 16-18), the current 
procedure involves the use of brief-pulse stimulation techniques which 
induct a series of generalized epileptic seizures under anesthesia and 
muscle relaxation. This procedure is “one of the best tolerated and safest 
biological treatment strategies with low risk for severe complications” 
(Eser et al. 2007, 2; see also Abrams 2002). A typical course of ECT 
treatment consists of two or three inductions a week for two to seven weeks 
(Fink 2009, 4). Fink explains the procedure as follows:  
 
The patient is asked to empty the bladder and is then taken to 
the treatment room, where she lies down on a stretcher. A nurse 
or physician inserts a needle into a vein in the arm or foot, 
attaches a bottle of fluid (usually sugar in water), and sets the 
fluid flowing at a slow rate. […] This intravenous line allows 
the easy and painless administration of medications during the 
treatment. Adhesive monitoring electrodes - flat, disposable 
pads or reusable discs to which electrical connections can be 
 
Kirov (2020). In the Bini archive, there are letters from patients containing thanks to Lucio 
Bini and Ugo Cerletti for the improvement of the conditions after the E.S. treatments. 
(Passione 2007, 89) 
10 “The EEG facilitates discrimination between electrode positions and different stimulus 
doses. […] EEG may indicate threshold changes highlighting the need to increase the 
stimulus dose or reduce the anesthetic induction agent” (Weiss 2018, 17). 
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made - are applied to the skin, a painless procedure. Three 
electrodes are put in place for the electroencephalogram 
(EEG); two stimulating electrodes for the electrical stimulus; 
three for the electrocardiogram (ECG) and heart rate; and two 
to measure motor movements during treatment. A recording 
electrode placed on the patient’s finger or toe measures the 
blood oxygen saturation. A blood pressure cuff on the arm 
measures the blood pressure, and a second one may be placed 
as a tourniquet on a leg to allow the psychiatrist to record the 
duration of the muscular signs of the seizure. (Fink 2009, 14)  
 
During the seizure, the medical team needs to monitor heart rate and 
rhythm, blood pressure and the brain’s electrical activity. Some dental 
conditions require a personalized plastic braces for each treatment. 
 
Electrodes placement affects the procedure: treatments based on bilateral 
electrode placement usually exhibit shorter duration.  The successful use 
of bilateral ECT is reported, for example, for severe forms of catatonia. I 
provide more details on this below. Another important issue is the 
combination of ECT therapy with antipsychotics. Since ECT is not 
considered as therapy of first choice in catatonia, patients often come to 
ECT after benzodiazepines administration or while they are receiving this 
medication. In these cases, a drastic withdrawal is not recommended, 
because it may cause worsening or relapse of the most severe symptoms. 
Indeed, a synergic effect of ECT and benzodiazepines has been reported 
by Petrides and colleagues, who also claim that “benzodiazepines are often 
useful and can be continued for many months after recovery” (Petrides et 
al. 2004, 156-157; Weiss 2018, 70-71). 
 
 
5. The Underlying Mechanism of ECT: A Neuroendocrinological 
Perspective 
 
An objective and scientific-based reason that can explain why ECT, by 
giving patients epileptic-like seizures, should be beneficial to some 
psychiatric illness remains quite obscure. What we know is that 
adrenocorticotropic hormone (ACTH), thyrotropin releasing hormone 
(TRH), and vasopressin are well-studied hormones that are known to be 
released by seizures. The amount of hormones released varies with 
electrode placement, stimulation dosage, number and frequency of 
treatments. Prolactin, for example, is quickly released within the serum 
with a peak at 20 minutes. According to Fink, “it is the massive outpouring 
of these hormones that characterize the seizures in effective ECT” (Fink 
2013, 21).  
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As it is known, the hypothalamus plays a crucial role in sustaining life 
because it regulates the autonomic nervous and neuroendocrine systems. 
We also know that hormonal functions in mental illness are disordered.  
For instance, in severe depressive states, the axis linking hypothalamus, 
pituitary gland, and adrenal and thyroid glands appears to be dysfunctional, 
involving increases of cortisol and other hormones. ECT with bitemporal 
electrode placement allows the passage of electricity from one temple to 
the other, and as a result the hypothalamus is directly stimulated. The first 
effects of such stimulation are transitory, but by the fourth or fifth 
stimulus—according to Max Fink—“the normal feedback actions of the 
hormones of the hypothalamic-pituitary-adrenal axis are again in place. 
Feeding and sleep become normal, and improvements in motor activity, 
mood, memory, and thought to follow quickly” (Fink 2013, 24). It is no 
coincidence that ECT is most effective in patients who present 
neuroendocrine dysfunctions (e.g. “abnormal dexamethasone suppression 
test or diminished thyroid-stimulating hormone response to thyrotropin-
releasing hormone”), which can disappear with effective treatment 
(Petrides et al. 2004, 158). 
 
However, the neurotransmitter pathway has also been explored to better 
understand the ECT effects. For what concerns depression, several studies show 
that ECT can attenuate serotonergic and noradrenergic neurotransmission (for a 
review see Eser et al. 2007, 3). Two phenomena have been observed in this 
respect. On the one hand, ECT would increase the availability of the serotonin 
precursor thus contributing to the therapeutic effects of ECT (Palmio et al. 2005). 
On the other hand, in line with the GABA deficit hypothesis of depression, ECT 
would exert a compensatory increase in γ-aminobutyric acid (GABA) 
neurotransmission. For instance, a study based on proton magnetic resonance 
spectroscopy showed that “occipital cortex GABA concentrations are increased 
in depressed patients treated with ECT” (Eser et al. 2007, 3; see also Sanacora et 
al. 2003). 
 
The behavioral effects of seizures require repetition until the pathological 
symptoms have remitted, and new patterns of behavior have stabilized. The 
prescription of antidepressants after a successful ECT administration 
reduces the risk of early relapse (Weiss 2018). As I mention above, 
antidepressants should not be suddenly discontinued before ECT, 
especially those with a short half-life or SSRIs. Those patients previously 
medicated with SSRIs should be initially administered “a low electrical 









Currently, the mortality rate of ECT is estimated at two deaths per 100,000 
treatments. The causes of death referring to adults during ECT are from 
cardiovascular disorders, most often pre-existing conditions, such as 
cardiac arrhythmia or hypertension, when these fail to be taken into 
account by clinical practitioners and anaesthesiologists. According to 
proton magnetic resonance spectroscopy studies, it seems that neuronal 
damage or cell death are not induced by ECT, because it does not provoke 
a significant decrease in the N-acetylaspartate signal, which constitutes a 
sign of cell atrophy (Ende et al. 2000; Eser et al. 2007, 4).  
 
No deaths have been ever reported in an adolescent or a child directly due 
to ECT. Mortality associated with ECT has markedly decreased with 
technological improvement and medical monitoring during the 
applications. For this reason, nowadays, ECT can be considered a low-risk 
procedure, “even among older patients with cardiac disorders” (Consoli et 
al. 2013, 141). Anaesthesia may obviously provoke other side effects, 
including disturbance in cardiac rhythm, variations in blood pressure, 
respiratory incidents, and allergic reactions. Less serious side effects of 
ECT include headache and muscle pain, nausea (with or without vomiting), 
temporary confusion immediately after the sessions, and understandable 
fear about ECT. “Up to 45% of patients report headache after ECT, which 
can be treated using analgesics such as acetylsalicylic acid or paracetamol 
and, if severe, by changing the induction medications” (Eser et al. 2007, 
10). Even if rarely, nausea may occur after intravenous anesthesia; in this 
case metoclopramide can be used successfully. Since ECT is not a first-
line treatment, when psychiatrists suggest or prescribe ECT, patients often 
present a very compromised medical status. When ECT is early 
administered in the course of catatonia and in severe forms of depression, 
then more favourable results and reduced morbidity are obtained. 
Furthermore, such severe psychiatric disorders often entail cognitive 
impairments per se. Thus, it is challenging to evaluate eventual cognitive 
damages due to ECT or to illness.  
 
In the last twenty years, an increasing number of studies have focused on 
ECT effects on memory. The meta-analysis conducted by Fraser and 
colleagues (Fraser et al. 2008) suggests that ECT may cause 
autobiographical memory impairment. Still, such memory loss is relatively 
short-term, i.e., about six months post-treatment. The potential cognitive 
deficits refer to autobiographical episodes and events that occurred in the 
period close to the beginning of treatment. Furthermore, implicit memory, 
procedural memory and semantic memory are not modified by ECT 
(Consoli et al. 2013). Therefore, it is reasonable to claim that memory loss 
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due to ECT is temporary and circumscribed to some particular events close 
to the sessions. The degree of these temporary memory damages depends 
on many factors such as the number of sessions, the features of the 
electrical current (e.g. brief pulsed or sinusoidal), the placement of the 
electrodes, and the presence of persistent depressive symptoms before ECT 
(Sackeim et al. 1991). In brief, variations in the administration 
methodology may affect cognitive function after ECT. From randomized 
studies, it seems that “sinusoidal waveform causes more memory 
impairment than brief-pulse ECT” (Lamprecht et al. 2005, 18), and, for 
this reason, brief-pulse stimulation techniques represent the most common 
stimulation method nowadays.   
 
This brief overview shows how 80 years after the invention and 
introduction of ECT, the methodology of its application has improved both 
to avoid collateral physical damage and to enhance the effectiveness of 




Given the importance of lateralization and, more generally, of the 
allocation of the electrodes for what concerns efficacy and risks of ECT, 
some further considerations are necessary. First, it is established that 
“stimulus intensity depends on electrode placement” (Eser et al. 2007, 5). 
In this sense, bilateral ECT seems to be more effective than unilateral (UL) 
ECT, which requires a higher stimulus dosage to gain the same results. 
Many practitioners doubt the effectiveness of UL ECT in treating patients 
who have severe or life-threatening psychopathologies (Weiss 2018). 
Consequently, the final choice of the more effective positioning of the 
electrodes requires a balance of costs and benefits for the suffering 
patients. The electrode placement, in fact, constitutes a crucial factor for 
cognitive side effects; in this regard, it seems that bifrontal electrode 
placement is as efficacious as bitemporal placement in inducing less severe 
cognitive impairment (Bailine et al. 2000).12 The UK ECT Review Group 
recommends that bilateral arrangement is preferred when rapid and 
complete recovery has priority, whereas UL is preferred when minimizing 
cognitive adverse effects has priority.   
 
When treatment is not urgent, an initial trial of unilateral ECT 
will significantly shift the cost–benefit balance because of the 
 
11 It is worth noting that the World Health Organization promoted the ban on 
unmodified ECT (Leiknes et al. 2012). 
12 Notably, in schizophrenic patients the influence of electrode placement (or stimulus 
intensity) is less obvious than in depressive patients (Eser et al. 2007). 
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substantial reduction in the risk of severe or persistent 
retrograde amnesia. […] Clinical monitoring of symptoms and 
possible cognitive adverse effects is necessary in any case 
throughout treatment, and a lack of satisfactory improvement 
may lead to an increase in the electrical dose or a switch to 
bilateral electrode placement if there had been no clinical 
improvement. (Scott 2005, 135-136)  
 
What is the optimal frequency of treatments? According to Scott (2005, 
141), in the case of bilateral treatment, the optimal frequency is twice per 
week, which may be reduced if cognitive adverse effects emerge. A three 
times per week administration could be justified only in severe, life-
threating depression, since it leads to a faster reduction of depressive 
symptoms, but “at the cost of more pronounced cognitive adverse effects” 
(Scott 2005, 140). For what concerns UL ECT, the optimal frequency 
seems to be twice per week. 
 
 
7. ECT in Pediatric Care 
 
The stigma of ETC is even more evident when talking about its 
applications in children and adolescents. Any public and professional 
discourse over ECT in minors is likely “to be emotive, rhetorical, and 
unbalanced” (Robertson et al. 2013, 59). A (young) person receiving ECT 
is liable to experience stigma because of his or her age, illness, and 
treatment. It is a fact that negative attitudes toward ECT contribute to this 
stigma, which entails negative consequences such as concealment of 
illness and social exclusion (McDonald and Walter 2013, 51). However, 
when people who hold these prejudices encounter individuals who have 
received ECT, or gain accurate information about the treatment, they view 
the treatment in a more positive light. As Fink claims, “patients undergoing 
ECT have proved to be its best advocates” (2009, 11). It is the case of 
young patients and their parents as the studies of Walter et al. (1999) and 
Flamerique et al. (2017) show. In both studies, the researchers used a self-
administered questionnaire to assess the experience, knowledge, and 
attitudes of parents of adolescents who had been treated with ECT about 
the treatment. In the former, 28 parents were interviewed and expressed 
favorable opinions about ECT: 17 of 28 parents claimed that ECT had been 
helpful. The latter investigated parents of adolescents (under the age of 18) 
diagnosed with schizophrenia and treated with ECT. They were compared 





Most parents in the ECT group claimed that they had received 
adequate information about the ECT procedure (94.7%), most 
of them thought it had been helpful for their children (73.7%) 
and none thought that it had made things worse. The large 
majority of parents in the ECT group (80%) thought that the 
illness had been worse than ECT or medication, and none 
thought that ECT was the worst. (Flamerique et al. 2017, 1) 
 
In adolescence,13 treatment-resistant mood disorder constitutes a severe 
debilitating illness which may be successfully treated with ECT when 
treatment resistance is well identified (Ghazziudin 2013). Depression and 
catatonia in children and adolescents constitute a severe and debilitating 
disorder that can be life-threatening, and even in less severe cases, it 
significantly affects the quality of life of patients and their families. 
Furthermore, these kinds of disorders negatively affect normal growth and 
development. The treatment of prepubescent children still occurs in rare 
cases, while for adolescents the scientific literature confirms that 
prescriptions, safety and efficacy are the same as for adults (Fink 2009, 
Abrams 2002; Fink and Taylor 2003; Cohen et al. 2000; Consoli et al. 
2012). 
 
Nevertheless, there is a gap in the guidelines of many national institutes 
when this unpleasant failure of treatment occurs. For example, the 
American Academy of Child and Adolescent Psychiatry Practice 
Parameters for the assessment and treatment of children and adolescents 
with depression do not include ECT as a treatment option. The first-line 
treatment of moderate to severe adolescent depression is usually SSRI 
combined with evidence-based psychotherapy (CBT or IPT). Failure to 
respond to one or two SSRIs is often followed by treatment with a 
noradrenergic antidepressant. Ghazziudin estimates that “approximately 
71% of adolescents may respond to initial combination treatment 
(fluoxetine and CBT) by the end of a 12-week period, although remission 
rates may be higher when treatment is administered over a longer duration” 
(Ghazziudin 2013, 185). It is worth noting that antipsychotic agents often 
have substantial side effects, such as weight gain and obesity associated 
with an elevated risk for diabetes mellitus (Holt 2019). Additionally, an 
increased risk of suicide rates has been associated with Antiepileptic drugs 
(AEDs), that can function as mood stabilizers and are often used for 
augmenting antidepressants. Still, they result in a “black box” warning by 
the US Food and Drug Administration (FDA). Ghazziudin found that “one 
in every four or five adolescents diagnosed with MDD may not respond to 
two sequentially used antidepressant agents administered inadequate dose 
 
13 ECT is an extremely rare procedure in children below 12 years of age. 
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and duration” (2013, 177). Some of these young patients might reasonably 
benefit from ECT.  
 
ECT side effects in adolescents 
 
ECT is usually well-tolerated by many adolescents. Some studies reported 
in Consoli et al. (2008, 155) indicate that “most former adolescent 
recipients report a positive experience and attitude toward ECT”, despite 
initial and understandable apprehension. The possible presence of 
cognitive impairments among adolescents treated by ECT has been 
analyzed by Ghazziudin and colleagues (2000): 
 
Comparison of pre-ECT and the first post-ECT testing 
administered during the first 10 days of the treatment yielded 
significant impairments of concentration and attention, verbal- 
and visual-delayed recall, and verbal fluency. A complete 
recovery of these functions was noted at the second post-ECT 
testing. There was no deficit in the ability to problem solve 
during the initial or the subsequent testing. (Ghazziudin et al. 
2000, 269, italics added) 
 
Although caution is in order while we wait for further confirmation from 
larger samples, these results attest the evidence already emerged among 
adults: there is no long-term injury in terms of concentration, attention, 
visual memory, and verbal fluency. Side effects of ECT in young persons 
are generally transient, as in the adult population. As David Cohen, director 
of the child and adolescent psychiatry service at the Pitié-Salpêtrière 
hospital group in Paris, claimed: “there is no ethical reason to ban ECT use 
in adolescents”. On the contrary, “unrealistic fears regarding ECT” lead to 




8. Legal and Ethical Concerns 
 
In the USA, despite the updated recommendations of the American 
Psychiatric Association (APA) for ECT practice, the legislative framework 
concerning ECT differs among the member States. For example, in 
California and Texas there is a stricter legislation than the norms 
recommended by the APA. The EU boasts the creation of a European 
Forum for Electroconvulsive Therapy (EFFECT – founded in 2005)14 and 
 
14 “EFFECT brought together clinicians and researchers to improve the practice of ECT, 
and to reduce its stigma” (https://www.theeffect.eu/). 
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a Task Force on ECT within the World Federation for Societies of 
Biological Psychiatry (WFSBP). Nevertheless, there is no unified 
European recommendation on ECT yet (Robertson et al. 2013). In Slovenia 
and Luxembourg, ECT is not available to treat people of any age. In 
Romania people are sometimes treated without anaesthesia because 
anaesthesiologists are not always available, while in Spain, Austria, 
Slovakia, Greece, Switzerland, and Germany, ECT is available and 
separate consent for anaesthesia is required (Gazdag et al. 2012, 6). In 
Italy, Ireland, and Latvia a written informative consent is needed for each 
ECT session, while in Portugal and the UK, one informative consent is 
valid for a definite number of sessions (12 or 15) (Gazdag et al. 2012). 
 
ECT is so stigmatized that its use is severely limited, and its merits are 
neglected or even denied. The numerous attacks that ECT has received are 
often supported by ideological reasons not based on science or clinical 
experience. Nevertheless, these attacks have obtained political attention 
and often led to legislative restrictions (Ottosson and Fink 2004, 19). 
Misconceptions regarding ECT are associated with negative attitudes 
toward it, but prejudices and folk beliefs should not be involved in the 
scientific, ethical, and political discourse. Psychiatry – as Shorter and Fink 
note - “has swung wildly from fashion to fashion from asylum care to 
psychoanalysis to lobotomy to psychopharmacology without having an 
underlying scientific rationale for doing so. More than any other medical 
field, psychiatry has been guided by cultural preferences and political 
persuasions” (Shorter and Fink 2010, vi). It is time to “regroup” and adopt 
a “multifaceted approach” to change this bleak picture (McDonald and 
Walter 2013, 51). We must surrender to the idea that there is a group of 
psychiatric patients who are drug-resistant, or they cannot assume drugs 
for several reasons. In a nutshell, the ethical puzzle that I raise is the 
following. Is it possible to administer a therapy to help these suffering 
patients (be them adults or minors)? If the answer is yes, at least for some 
types of severe diseases, why should we refrain from administering that 
therapy? Why should we ignore, for ideological reasons, robust therapeutic 
possibilities? Why should we prolong the severity of the symptoms by 
making the life of patients and their family members unbearable? One 
therapy for the improvement of some severe psychotic symptoms exists 
and is practicable. ECT is such a therapy. In this sense, ECT does not 
constitute an alternative model of treatment, but an additional therapeutic 
tool that does not replace, but rather integrates pharmacotherapy and 
psychotherapy. 
 
In conclusion, it is worth noting that the last decades have seen the 
promising development of several invasive treatments for brain stimulation 
aimed to relieve severe neuropsychological impairments in neurological 
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and psychiatric patients, like for example Transcranial Magnetic 
Stimulation (TMS), and Deep Brain Stimulation (DBS) (see Pycroft et al. 
2018 for a review). If ECT is a well-established treatment for depression 
and catatonia, DBS is applied in patients who have severe Parkinson’s 
disease, as well as depression (Marcolin and Padberg 2007, vii). Many of 
these brain stimulation techniques “converge in terms of underlying 
mechanisms of action based on fundamental principles of brain function” 
and differentiate each other in virtue of specific characteristics regarding 
the levels of invasiveness and the duration of intervention (Ibid., viii). For 
example, DBS, is, de facto, a permanent stimulator into the brain and it 
represents “a long-term treatment, particularly suitable for chronic or 
frequently relapsing disorders” (Ibid.). These novel methods find great 





Electroconvulsive Therapy represents an appropriate treatment for 
severely ill psychiatric patients who need hospital care. In those Western 
countries where ECT is permitted and practiced, it is usually recommended 
after long, unsuccessful courses of psychotherapies and psychotropic 
drugs. To summarize in a nutshell the current practice, I follow Yuval 
Bloch’s words, according to whom the major reason for child and 
adolescents referrals to ECT is represented by the severity of symptoms, 
particularly catatonia and suicidal behaviour, while the major reason for 
referral of adults is the long and persistent failure of response to 
pharmacotherapy (Bloch et al. 2008). In this paper I set out to show that a 
further step is possible to promptly provide appropriate and effective care 
in those difficult cases. However, a cultural change is necessary to get 
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